Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

"Time Is Brain" - for Cell Therapies

Yin H., Brian D., Weber RZ., Lyden PD., Rust R.

Narrative Review on Stroke Research, Immune Modulation, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Sci (Weinh) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41250948
PMCID
PMC12866691
DOI
10.1002/advs.202519579
Citations
2

Abstract (original English)

The principle "time is brain" has long guided acute stroke treatment, emphasizing that earlier intervention improves outcomes. While this dictum applies to current gold-standard reperfusion therapies, its relevance to emerging regenerative approaches such as stem cell therapy remains to be established. A growing body of preclinical and clinical studies suggests that timing of cell delivery is a key determinant of graft survival, integration and therapeutic efficacy, largely through interactions with the evolving post-stroke microenvironment. Here, we discuss how early transplantation may access salvageable tissue but faces a hostile inflammatory microenvironment, whereas transplantation at the subacute or chronic phase benefits from a more permissive milieu but by then much of the tissue has been irreversibly lost. We further suggest the optimal window also depends on cell type and mechanism of action: neuroprotective or immunomodulatory grafts may benefit from earlier delivery, while cells requiring long-term survival and integration may perform better later. Thus, "time is brain" also applies to cell therapies, but it may require aligning graft delivery with the evolving post-stroke microenvironment rather than the acute therapeutic window. Identifying biomarkers that track inflammatory changes, vascular remodeling and brain damage could personalize this "window of receptivit

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
BrainAnimalsHumansStem Cell TransplantationStrokeCell- and Tissue-Based Therapy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research